linjc16/ctgov huggingface dataset:
Burden of Cervical Cancer in Tanzania

Study Overview
=================
Brief Summary
-----------------
Cervical cancer screening is a worldwide problem especially in the developing world of which Tanzania belongs. It is diagnosed late in the third world because there are no diagnostic facilities and resource people. It occurs in the age groups between 40 and above and therefore affects the productive age of the community. It is well known that women generally are the backbone of every community and specifically in the developing countries. The objective of this research is to analyze and quantify the burden of cervical cancer disease in the community. It will research the interpersonal and socioeconomic issues associated with cervical cancer disease in the family.

Official Title
-----------------
Survey Assessment and Projection of the Social and Economic Burdens of Cervical Cancer in Tanzania

Conditions
-----------------
Cervical Cancer, -Socioeconomic Burden of Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: new pathological diagnosis of cervical cancer Exclusion Criteria: non consenting individuals

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Terminal Disease<br>Terminal cervical cancer- not treatable | |
| Early Disease<br>Early cervical cancer = meaning treatable with hysterectomy. | |
| Advanced Disease<br>Advanced cervical cancer- treatable with chemotherapy and/or radiation. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Socioeconomic burden to households | share of household consumption attributable to medical care (hospitals, dispensaries, etc.) monthly household income (work hours, income sources, changes in the type or amount) child school attendance, nutrition (school days missed in past week, meals eaten, source of proteins on day prior to interview) | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Projection of economic impact on community | Combine rates of cervical cancer with the age and gender distribution in the Kilimanjaro Region (Tanzania Census), distribution of cancer stages, and primary outcomes from the study cohort to estimate of total medical expenses, income losses, and school days missed due to cervical cancer. | 12 months |
Testosterone Replacement in Renal Failure

Study Overview
=================
Brief Summary
-----------------
The purpose of this trial is to evaluate the effect of testosterone replacement in men with renal failure (on dialysis) who also have low testosterone. Specifically, the investigators will assess the change in requirement of Erythropoietin Stimulating agents.

Detailed Description
-----------------
Testosterone replacement can increase hemoglobin count. This can therefore decrease the requirement of Erythropoietin Stimulating agents.

Official Title
-----------------
Effect of Testosterone Replacement on Erythropoietin Stimulating Agent Use in End Stage Renal Disease Patients

Conditions
-----------------
Hypogonadism

Intervention / Treatment
-----------------
* Drug: Testosterone
* Drug: Saline


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Men between ages of 18-80 years of age. Renal failure on hemodialysis Free testosterone <5 ng/dl. Willing to be randomized to intramuscular (IM) testosterone or placebo Currently getting intravenous Epoetin alfa Exclusion Criteria: Use of testosterone treatment currently or in the past 6 months, including use of over the counter androgen containing health supplements. Congestive heart Failure, class III or IV. Baseline hemoglobin of > 12 g/dl. Allergic reactions to testosterone Vehicle (i.e. Peanut oil) prostate specific antigen>4 ng/ml. History of Prostate Cancer. Liver enzymes >twice the upper limit of normal. HIV or hepatitis C. Severe untreated obstructive sleep apnea (defined as apnea-hypopnea index> 30). Subjects on warfarin or other blood thinners. Active infection (such as foot ulcer) History of adverse events with testosterone use in past.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Testosterone<br>Testosterone intramuscular every 2 weeks | Drug: Testosterone<br>* Testosterone<br>|
| Placebo Comparator: Saline<br>Saline intramuscular every 2 weeks | Drug: Saline<br>* Placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in dosage of Erythropoietin stimulating agents (ESA) | Comparison of dose of ESA in the 2 months prior to the start of the drug and in months 5 and 6. | primary outcome will be measured at months 5 and 6. |
Integrated Positron Emission Tomography - Computed Tomography (PET-CT) in Patients With Pancreatic Cancer

Study Overview
=================
Brief Summary
-----------------
In suspecting pancreatic cancer, dynamic phase pancreatic CT is the most effective tool in diagnosis and staging. In addition, magnetic resolution image, endoscopic ultrasonography, endoscopic retrograde pancreatography, angiography can be performed. After introduction of functional image, PET has been suggested in the role of diagnosis and staging of pancreatic cancer. Furthermore, recently fused images of PET and CT were available. In this study, the researchers evaluate the role of integrated PET-CT in patients with pancreatic cancer and analysis the cost-effectiveness of the integrated PET-CT.

Detailed Description
-----------------
Compared to dynamic phase pancreatic CT, integrated PET-CT will be evaluated for sensitivity, specificity and accuracy of diagnosing and staging pancreatic cancer while the gold standard for pancratic cancer is operative specimen. If the operation can't be performed, EUS-FNA of the pancreatic mass or lymph node and additional imaging modality will be preferred to laparotomy.

Official Title
-----------------
Clinical Implication of Integrated PET-CT in the Patients With Pancreatic Cancer

Conditions
-----------------
Pancreatic Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pancreatic mass suspicious of pancreatic cancer No comorbidity, expected life expectancy less than 6 months Consent this study in letter Exclusion Criteria: Refuse diagnostic and staging work-up

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Staging of pancreatic cancer |  | 6 months after study start | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diagnosis of pancreatic cancer |  | 6 months after study start | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pancreatic cancer, integrated PET-CT
Adenoma Detection by Polypectomy During Both Insertion and Withdrawal

Study Overview
=================
Brief Summary
-----------------
Standard method of colonoscopy is to insert the colonoscope rapidly to reach the cecum, with careful inspection and polypectomy during the withdrawal phase. However, small polyps (e.g. <1cm) seen during insertion phase are difficult to find during withdrawal phase. Also, colon is in different conformation during insertion and withdrawal phases. We think careful inspection and polypectomy during both insertion and withdrawal can improve adenoma detection rate.

Official Title
-----------------
Comparison of Adenoma Detection by Polypectomy During Both Insertion and Withdrawal Versus Only Withdrawal of Colonoscopy: a Randomized, Controlled Trial

Conditions
-----------------
Adenoma of Large Intestine

Intervention / Treatment
-----------------
* Procedure: Both insertion and withdrawal
* Procedure: Only withdrawal


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient undergoing screening or surveillance colonoscopy Exclusion Criteria: Previous colorectal resection, Polyposis syndrome, Inflammatory bowel disease

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Both insertion and withdrawal<br> | Procedure: Both insertion and withdrawal<br>* inspection and polypectomy during both insertion and withdrawal of colonoscopy<br>|
| Active Comparator: Only withdrawal<br> | Procedure: Only withdrawal<br>* inspection and polypectomy during only withdrawal of colonoscopy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adenoma detection rate |  | 4 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of adenoma per patient |  | 4 weeks |
Pre-operative Focused Transthoracic Echocardiography for Prediction of Post-operative Cardiac Complications

Study Overview
=================
Brief Summary
-----------------
The extent focused transthoracic echocardiography when done pre-operatively to patients admitted for elective surgery and suspected to be at risk of cardiac disease specially the geriatric population can affect perioperative anesthetic management of these patients.

Official Title
-----------------
Pre-operative Focused Transthoracic Echocardiography for Prediction of Post-operative Cardiac Complications

Conditions
-----------------
Diastolic Dysfunction

Intervention / Treatment
-----------------
* Diagnostic Test: TRANSTHORACIC ECHOCARDIOGRAPY


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients above 60 years of age ASAI and ASA II were included Exclusion Criteria: history of cardiac disease, history of previous postoperative cardiac complications and symptoms or signs of cardiac diseases.

Ages Eligible for Study
-----------------
Minimum Age: 60 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: TRANSTHORACIC ECHOCARDIOGRAPY|TTE (Vivid I echocardiography machine General Electric Healthcare, Milwaukee, WI, USA) with a 3S-RS (1.5-3.6 MHz) transthoracic probe). was done by professional anesthesiologist following the :Hemodynamic Echocardiography Assessment in Real Time ( HEART) protocol. According to the clinical findings of TTE patients may be either free or have one or more of the following haemodynamic states normal, empty, vasodilated ,left ventricular systolic or diastolic failure, left ventricular systolic and diastolic failure, and right ventricular failure, valve stenosis or regurgitation of at least moderate severity|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Lt. Ventricular EDV | Transthoracic echocardiography (TEE) LVEDV | Change from Baseline pre operative LVEDV to first day postoperative |
Adavanced Glycated Endproducts and Development of CAD

Study Overview
=================
Brief Summary
-----------------
Blood sample is prospectively taken from consecutive patients underwent coronary angiogram in our center, after getting informed consent from the patients. Serum level of advanced glycation end products (AGEs) was measured and the clinical features of patients (including angiographic results) were entered into our database. Clinical follow-up was performed for all patients, and the relationship between AGEs and paitents' outcome were analyzed. Further intervention will be adjusted according to the results,including clinical and basic research in lab.

Detailed Description
-----------------
Serum levels of HMGB1, HMGB2, ADAM10, etc. will be measured in lab and animal studies will be designed to intervene the adverse interaction between abnormal serum concentration of AGEs, etc. and worse clinical results.

Official Title
-----------------
Study of Serum Level of Advanced Glycated Endproducts and Development of Coronary Atherosclerosis in Patients Undergoing Coronary Angiogram

Conditions
-----------------
Atherosclerosis, Inflammation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients underwent coronary angiogram for suspected coronary artery disease and potential percutaneous coronary intervention Exclusion Criteria: patients underwent coronary angiogram for other reasons, including pre-surgery examination patients with severe co-morbidity, and life expectancy less than one-year

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| MACE | including death, occurrence of myocardial infarction, and coronary revascularization | 5-year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| progression in coronary atherosclerosis | repeated coronary angiogram in patients with symptom aggravation or occurrence of myocardial infarction, to evaluate the progression of coronary lesions, comparing to the baseline results. | 5-year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Advanced glycation end product, coronary, atherosclerosis, inflammation, outcome
Study of DMXAA (Now Known as ASA404) in Solid Tumors

Study Overview
=================
Brief Summary
-----------------
This is a phase I study aimed at identifying safe doses of DMXAA in patients with solid tumors.

Detailed Description
-----------------
This is a dose escalation study conducted at a single center in New Zealand. Patients received dimethylxanthenone acetic acid (DMXAA) IV over 20 minutes once every three weeks, up to a maximum of 12 courses. Cohorts of 3 patients received escalated doses of DMXAA until the maximum tolerated dose (MTD) was determined. The MTD is defined as the dose preceding that at which 2 of 3 patients experience dose limiting toxicity. Patients had solid tumors for which there was no standard therapy or were refractory to conventional therapy.

Official Title
-----------------
Phase I Trial of 5,6 Dimethylxanthenone - 4 - Acetic Acid (DMXAA) in Solid Tumors

Conditions
-----------------
Solid Tumors

Intervention / Treatment
-----------------
* Drug: DMXAA


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histologically confirmed solid tumor that is not amenable to any standard therapy or is refractory to conventional therapy Performance status WHO 0-2 Life expectancy greater than 3 months Hemoglobin at least 90 g/L; WBC at least 3,000/mm3; Platelet count at least 100,000/mm3 Bilirubin within normal limits; ALT less than 2 times upper limit of normal (ULN); Alkaline phosphatase less than 2 times ULN Creatinine less than 130 umol/L INR and APTT within normal limits Fertile patients must use effective contraception At least 4 weeks since prior anticancer therapy and recovered from toxic effects Exclusion Criteria: Concurrent malignancy except cone biopsied carcinoma in situ of the cervix and adequately treated basal or squamous cell carcinoma of the skin Other serious medical condition Uncontrolled infection or serious infection within the past 28 days Pregnant or lactating Treatment with glucocorticosteroids within previous two weeks

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: DMXAA|Administered as a 20 minute IV infusion, once every three weeks at doses ranging from 6 mg/m2 to 4900 mg/m2|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Toxicity of DMXAA |  |  | 
| Maximum tolerated dose of DMXAA |  |  | 
| Pharmacokinetics of DMXAA |  |  | 
| Effect of DMXAA on coagulation parameters, TNF and other cytokine production, nitric oxide, and serotonin production |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy of DMXAA |  |  | 
| Effect of DMXAA on tumor vasculature |  |  |
Using Digital Health Technologies to Prevent Rapid Infant Weight Gain.

Study Overview
=================
Brief Summary
-----------------
A digital intervention to provide supplemental infant feeding support to mothers enrolled in WIC. The trial begins prenatally and continues through 3-months postpartum and tests the feasibility and acceptability of a text messaging intervention aimed at increasing responsive bottle feeding as well as breastfeeding duration and exclusivity among mothers enrolled in WIC using evidence-based components such as interactive self-monitoring and feedback.

Official Title
-----------------
Using Digital Health Technologies to Prevent Rapid Infant Weight Gain.

Conditions
-----------------
Breastfeeding, Bottle Feeding, Child Obesity

Intervention / Treatment
-----------------
* Behavioral: Intervention
* Behavioral: Text4Baby


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Enrolled in WIC, English or Spanish speaking, at least 18 years old, between 18-28 weeks' gestation, and planning to remain enrolled in WIC for 6 months, intention to breastfeed or undecided about breastfeeding, and willingness to send and receive daily text messages. Exclusion Criteria: Postpartum exclusions include infant prematurity (<37 weeks), >3 days in neonatal intensive care unit, major medical problem affecting breastfeeding (i.e., maternal HIV), or birth weight <5 lbs.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Intervention<br>Interactive text messages that include goal setting, tailored feedback, and skills training. | Behavioral: Intervention<br>* The intervention aims to support infant feeding decisions and teach responsive feeding strategies.<br>|
| Active Comparator: Control<br>Text4Baby | Behavioral: Text4Baby<br>* Free health and wellness text messages timed to due date through pregnancy and up until the baby's first birthday.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Engagement | Percent of text messages responded to as measured by text log. | 32 weeks gestation to 3 months postpartum | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Breastfeeding duration | Number of weeks breastfed as measured by patient response. | 0 to 3 months postpartum |
Effects of Pursed-lip Breathing on Exercise Tolerance and Dynamic Hyperinflation in COPD

Study Overview
=================
Brief Summary
-----------------
Pursed-lip breathing (PLB) has been advocated to reduce respiratory rate and improve oxygen saturation in patients with chronic obstructive pulmonary disease (COPD) at rest. Although PLB is a strategy that potentially reduces expiratory flow limitation, there are only few studies addressing its effects on exercise. This study aimed to assess the ability of PLB to change the breathing pattern, degree of dynamic hyperinflation (DH) and arterial oxygenation in COPD patients during exercise. Exercise tolerance was evaluated by endurance time and respiratory mechanics was evaluated by forced oscillation technique.

Official Title
-----------------
Effects of Pursed-lip Breathing on Exercise Tolerance and Dynamic Hyperinflation in Chronic Obstructive Pulmonary Disease

Conditions
-----------------
Chronic Obstructive Pulmonary Disease

Intervention / Treatment
-----------------
* Behavioral: Pursed-lip breathing
* Behavioral: Normal Breathing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of chronic obstructive pulmonary disease (COPD) Regular treatment at Clementino Fraga Filho University Hospital (UFRJ) Exclusion Criteria: Exacerbation in the preceding 4 weeks SpO2<85% at peak exercise Other diseases that may contribute to dyspnea and exercise intolerance

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Pursed-lip Breathing<br> | Behavioral: Pursed-lip breathing<br>* Pursed-lip breathing involves a nasal inspiration followed by expiratory blowing against partially closed lips, avoiding forceful exhalation.<br>Behavioral: Normal Breathing<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Endurance time |  | within the first 01 hour | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| inspiratory capacity |  | within the first 01 hour | 
| oxygen saturation |  | within the first 01 hour | 
| dyspnea |  | within the first 01 hour | 
| forced oscillation variables |  | within the first 01 hour | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
exercise tolerance, dynamic hyperinflation, respiratory mechanics